MBOT trades 189.5% below Wall Street's consensus target of $5.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MBOT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Microbot Medical Inc. (MBOT) has a Wall Street consensus price target of $5.50, based on estimates from 3 covering analysts. With the stock currently trading at $1.90, this represents a potential upside of +189.5%. The company has a market capitalization of $87M.
Analyst price targets range from a low of $5.50 to a high of $5.50, representing a 0% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, MBOT trades at a trailing P/E of -6.6x. Analysts expect EPS to grow -59.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SSYSStratasys Ltd. | $707M | $8.21 | $12.50 | +52.3% | Buy | 68.4x | 36 |
RBOTVicarious Surgical Inc. | $1M | $0.16 | — | — | — | — | — |
TRVITrevi Therapeutics, Inc. | $2.8B | $19.50 | $25.00 | +28.2% | Buy | — | 17 |
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.30 | $82.40 | +81.9% | Buy | 13.5x | 44 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
ZBHZimmer Biomet Holdings, Inc. | $17.5B | $89.41 | $96.33 | +7.7% | Hold | 10.5x | 42 |
Quick answers to the most common questions about buying MBOT stock.
The consensus Wall Street price target for MBOT is $5.5, representing 189.5% upside from the current price of $1.9. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MBOT has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $5.5 implies 189.5% upside from current levels.
MBOT's current price is $1.9 with a consensus target of $5.5 (189.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5.5 for MBOT, while the most conservative target is $5.5. The consensus of $5.5 represents the median expectation. These targets typically reflect 12-month expectations.
MBOT is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MBOT stock forecast based on 3 Wall Street analysts shows a consensus price target of $5.5, with estimates ranging from $5.5 (bear case) to $5.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on MBOT, with a "Buy" consensus rating and $5.5 price target (189.5% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MBOT analyst price targets range from $5.5 to $5.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.